Table 1 |
|||
|
Patient characteristics at baseline and at 2-year follow-up |
|||
|
Variable |
n |
Baseline |
At 2-year follow-up |
|
|
|||
|
Demographic |
|||
|
Age (years) |
215 |
57.4 (49.1–64.7) |
|
|
Female |
215 |
170 (79.0%) |
|
|
Menopause |
170 |
111 (65.3%) |
|
|
Body mass index (kg/m2) |
215 |
23.9 (21.3–26.2) |
24.0 (21.5–26.2) |
|
Smoker |
210 |
65 (31.0%) |
67 (31.9%) |
|
Disease |
|||
|
Disease duration (years) |
215 |
9 (4–16) |
|
|
Age at disease onset (years) |
215 |
45.0 (33.0–53.0) |
|
|
Rheumatoid factor-positive |
202 |
97 (48.0%) |
|
|
Physician's global assessment score (visual analogue scale, 0–100 mm) |
203 |
19.0 (8.0–39.8) |
17.6 (8.5–30.0) |
|
Modified Health Assessment Questionnaire (range 1–4) |
214 |
1.50 (1.13–1.75) |
1.50 (1.13–1.87) |
|
Erythrocyte sedimentation rate (mm/hour) |
210 |
16 (9–27) |
14 (8–27) |
|
Disease activity score including 28 joints |
202 |
4.04 (3.17–4.96) |
4.26 (3.36–5.06) |
|
Medication |
|||
|
Ever user of disease-modifying antirheumatic drugs |
213 |
177 (83.1%) |
177 (83.1%) |
|
Corticosteroids |
208 |
79 (37.9%) |
85 (40.9%) |
|
User of corticosteroids in the 2-year period |
208 |
93 (44.7%) |
|
|
Antiresorptive osteoporosis treatment |
209 |
47 (22.5%) |
68 (32.5%) |
|
Ever user of antiresorptive osteoporosis treatment |
209 |
92 (44.0%) |
|
|
Calcium and/or vitamin D |
210 |
113 (53.8%) |
155 (73.8%) |
|
|
|||
|
Data presented as the median (interquartile range) or as the absolute value (%). |
|||
|
Hoff et al. Arthritis Research & Therapy 2007 9:R81 doi:10.1186/ar2280 |
|||
